CoChat

Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study

Open access
Farr, Olivia M., Tsoukas, Michael A., Triantafyllou, Georgios, Dincer, Fadime, Filippaios, Andreas, Ko, Byung-Joon, Mantzoros, Christos S. · 2016 · Metabolism
Cited by 105

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Background GLP-1 agonists, including liraglutide, have emerged as effective therapies for type 2 diabetes (DM) and obesity. Here, we attempted to delineate how liraglutide, at doses approved for DM, may impact circulating hormones influencing energy homeostasis in diabetics. Basic Procedures Using a randomized, placebo-controlled, double-blind, cross-over trial of 20 patients with type 2 diabetes, we examined the effects of liraglutide as compared to placebo on fasting levels of circulating hormones important to energy homeostasis, including leptin, ghrelin, PYY, and GIP. After 17 days (0.6 mg for 7 days, 1.2 mg for 7 days and 1.8 mg for 3 days) of treatment, we also studied changes in fMRI responses to food cues. Main Findings By design, to avoid any confounding by weight changes, subjects were studied for 17 days, i.e. before body weight changed. Participants on liraglutide had significantly increased GLP-1 levels (p<0.001), decreased percent change in leptin levels (p<0.01) and increased GIP levels (p<0.03) in comparison to placebo treated subjects. Whole brain regressions of functional activity in response to food cues reveal that increased GIP levels were associated with deactivation of the attention- and reward-related insula. Decreases in leptin levels were associated with activations in the reward-related midbrain, precuneus, and dorsolateral prefrontal cortex (DLPFC), and sensorimotor-related motor cortex and with deactivations in the attention-related parietal cortex and the cognitive control-related thalamus and pre-SMA. Principal Conclusions We demonstrate herein short-term changes to circulating levels of GIP and leptin in response to GLP-1 agonist liraglutide therapy. These findings suggest that liraglutide may alter the circulating levels of hormones important in energy homeostasis that, in turn, influence CNS perception of food cues. This could possibly lead to compensatory changes in energy homeostasis that would over time limit the efficacy of liraglutide to decrease body weight. These novel findings, which, pointing to the potential advantages of combination therapies, may have therapeutic implications, will need to be confirmed by larger and longer-term trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.metabol.2016.03.009

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 54

  1. Hotamisligil, 2006, Inflammation and metabolic disorders, Nature, 444, 10.1038/nature05485 · DOI · Paper page
  2. Aronis, 2014, Potential cardioprotective action of glp-1: from bench to bedside, Metabolism, 63, 979, 10.1016/j.metabol.2014.05.009 · DOI
  3. Vilsboll, 2007, Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes, Diabetes Care, 30, 1608, 10.2337/dc06-2593 · DOI · Paper page
  4. Sisley, 2014, Neuronal glp1r mediates liraglutide's anorectic but not glucose-lowering effect, J Clin Invest, 124, 2456, 10.1172/JCI72434 · DOI · Paper page
  5. Farr, 2014, Leptin therapy alters appetite and neural responses to food stimuli in brain areas of leptin-sensitive subjects without altering brain structure, J Clin Endocrinol Metab, 99, E2529, 10.1210/jc.2014-2774 · DOI · Paper page
  6. Konturek, 2003, Brain-gut axis in pancreatic secretion and appetite control, J Physiol Pharmacol, 54, 293
  7. Konturek, 2003, Neuroendocrinology of the pancreas; role of brain-gut axis in pancreatic secretion, Eur J Pharmacol, 481, 1, 10.1016/j.ejphar.2003.08.042 · DOI · Paper page
  8. Orr, 2005, Dietary influences on peripheral hormones regulating energy intake: potential applications for weight management, J Am Diet Assoc, 105, 1115, 10.1016/j.jada.2005.04.005 · DOI
  9. Farr, 2016, Diabetologia
  10. Harder, 2004, The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes, Diabetes Care, 27, 1915, 10.2337/diacare.27.8.1915 · DOI · Paper page
  11. Chan, 2003, The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men, J Clin Invest, 111, 1409, 10.1172/JCI200317490 · doi:10.1172/jci200317490 · Paper page
  12. Larsen, 2001, Systemic administration of the long-acting glp-1 derivative nn2211 induces lasting and reversible weight loss in both normal and obese rats, Diabetes, 50, 2530, 10.2337/diabetes.50.11.2530 · DOI · Paper page
  13. Clemmensen, 2014, Glp-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet, Diabetes, 63, 1422, 10.2337/db13-1609 · DOI · Paper page
  14. Al-Barazanji, 2000, Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) zucker rats, Obes Res, 8, 317, 10.1038/oby.2000.38 · DOI · Paper page
  15. Aziz, 2005, Hyperglycemia after protein ingestion concurrent with injection of a glp-1 receptor agonist in rats: A possible role for dietary peptides, Am J Physiol Regul Integr Comp Physiol, 289, R688, 10.1152/ajpregu.00850.2004 · DOI
  16. He, 2010, Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice, PLoS One, 5, e14205, 10.1371/journal.pone.0014205 · DOI · Paper page
  17. Patel, 2013, Co-agonist of glucagon and glp-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese c57 mice, Can J Physiol Pharmacol, 91, 1009, 10.1139/cjpp-2013-0189 · DOI
  18. Patel, 2013, Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (−4 db/db)*, J Diabetes, 5, 163, 10.1111/j.1753-0407.2012.00227.x · DOI
  19. Pocai, 2009, Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, Diabetes, 58, 2258, 10.2337/db09-0278 · DOI · Paper page
  20. Su, 2008, Boc5, a non-peptidic glucagon-like peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice, PLoS One, 3, e2892, 10.1371/journal.pone.0002892 · DOI · Paper page
  21. Claret, 2004, S 23521 decreases food intake and body weight gain in diet-induced obese rats, Obes Res, 12, 1596, 10.1038/oby.2004.199 · DOI
  22. Liu, 2014, The anorexic effect of ex4/fc through glp-1 receptor activation in high-fat diet fed mice, Acta Biochim Biophys Sin (Shanghai), 46, 675, 10.1093/abbs/gmu044 · DOI
  23. Malendowicz, 2003, Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats, Int J Mol Med, 11, 763
  24. Perez-Tilve, 2007, Exendin-4 potently decreases ghrelin levels in fasting rats, Diabetes, 56, 143, 10.2337/db05-0996 · DOI · Paper page
  25. Daousi, 2013, Acute peripheral administration of synthetic human glp-1 (7-36 amide) decreases circulating il-6 in obese patients with type 2 diabetes mellitus: A potential role for glp-1 in modulation of the diabetic pro-inflammatory state?, Regul Pept, 183, 54, 10.1016/j.regpep.2013.03.004 · DOI
  26. Diaz-Soto, 2014, Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with type 2 diabetes: A prospective study, Diabetes Res Clin Pract, 104, 92, 10.1016/j.diabres.2014.01.019 · DOI
  27. Drewes, 1997, A liquid mixed meal or exogenous glucagon-like peptide 1 (glp-1) do not alter plasma leptin concentrations in healthy volunteers, Acta Diabetol, 34, 230, 10.1007/s005920050079 · DOI
  28. Gutzwiller, 1999, Glucagon-like peptide-1: A potent regulator of food intake in humans, Gut, 44, 81, 10.1136/gut.44.1.81 · DOI · Paper page
  29. Shalev, 1997, Absence of short-term effects of glucagon-like peptide-1 and of hyperglycemia on plasma leptin levels in man, Metabolism, 46, 723, 10.1016/S0026-0495(97)90112-8 · DOI
  30. Wada, 2014, Leptin and its receptors, J Chem Neuroanat, 61–62, 191, 10.1016/j.jchemneu.2014.09.002 · DOI
  31. Farr, 2015, Leptin and the brain: influences on brain development, cognitive functioning and psychiatric disorders, Metabolism, 64, 114, 10.1016/j.metabol.2014.07.004 · DOI
  32. Le, 2006, Less activation of the left dorsolateral prefrontal cortex in response to a meal: A feature of obesity, Am J Clin Nutr, 84, 725, 10.1093/ajcn/84.4.725 · DOI · Paper page
  33. Le, 2007, Less activation in the left dorsolateral prefrontal cortex in the reanalysis of the response to a meal in obese than in lean women and its association with successful weight loss, Am J Clin Nutr, 86, 573, 10.1093/ajcn/86.3.573 · DOI
  34. Rosen, 2015, Functional mri reveals a cognitive control subnetwork supporting long-term memory-guided visual attention, J Vis, 15, 1247, 10.1167/15.12.1247 · doi:10.1167/15.12.1247
  35. Neale, 2015, Functional activation during the rapid visual information processing task in a middle aged cohort: An fmri study, PLoS One, 10, e0138994, 10.1371/journal.pone.0138994 · DOI · Paper page
  36. Mason, 2015, Attentional bias predicts increased reward salience and risk taking in bipolar disorder, Biol Psychiatry
  37. Hosseini, 2015, Reward feedback stimuli elicit high-beta eeg oscillations in human dorsolateral prefrontal cortex, Sci Rep, 5, 13021, 10.1038/srep13021 · DOI
  38. Irlbacher, 2014, Mechanisms and neuronal networks involved in reactive and proactive cognitive control of interference in working memory, Neurosci Biobehav Rev, 46, 58, 10.1016/j.neubiorev.2014.06.014 · DOI
  39. Prevosto, 2013, Cognitive control of movement via the cerebellar-recipient thalamus, Front Syst Neurosci, 7, 56, 10.3389/fnsys.2013.00056 · DOI
  40. Corbetta, 2002, Control of goal-directed and stimulus-driven attention in the brain, Nat Rev Neurosci, 3, 201, 10.1038/nrn755 · DOI · Paper page
  41. McFadden, 2013, Effects of exercise on resting-state default mode and salience network activity in overweight/obese adults, Neuroreport, 24, 866, 10.1097/WNR.0000000000000013 · DOI · Paper page
  42. Polania, 2015, The precision of value-based choices depends causally on fronto-parietal phase coupling, Nat Commun, 6, 8090, 10.1038/ncomms9090 · DOI · Paper page
  43. Deacon, 2011, Physiology of incretins in health and disease, Rev Diabet Stud, 8, 293, 10.1900/RDS.2011.8.293 · DOI · Paper page
  44. Deacon, 2005, What do we know about the secretion and degradation of incretin hormones?, Regul Pept, 128, 117, 10.1016/j.regpep.2004.06.007 · DOI · Paper page
  45. El-Ouaghlidi, 2007, The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion, J Clin Endocrinol Metab, 92, 4165, 10.1210/jc.2006-1932 · DOI · Paper page
  46. Woerle, 2012, The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes, Diabetes, 61, 2349, 10.2337/db11-1701 · DOI · Paper page
  47. Lund, 2011, The separate and combined impact of the intestinal hormones, gip, glp-1, and glp-2, on glucagon secretion in type 2 diabetes, Am J Physiol Endocrinol Metab, 300, E1038, 10.1152/ajpendo.00665.2010 · DOI · Paper page
  48. Rolls, 2015, Taste, olfactory, and food reward value processing in the brain, Prog Neurobiol, 127–128, 64, 10.1016/j.pneurobio.2015.03.002 · DOI · Paper page
  49. Rolls, 2015, Functions of the anterior insula in taste, autonomic, and related functions, Brain Cogn
  50. Val-Laillet, 2015, Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity, Neuroimage Clin, 8, 1, 10.1016/j.nicl.2015.03.016 · DOI · Paper page
  51. Wang, 2015, Reward breaks through center-surround inhibition via anterior insula, Hum Brain Mapp, 10.1002/hbm.23004 · DOI
  52. Wijngaarden, 2015, Obesity is marked by distinct functional connectivity in brain networks involved in food reward and salience, Behav Brain Res, 287, 127, 10.1016/j.bbr.2015.03.016 · DOI
  53. Nyberg, 2007, Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain, J Neurosci Res, 85, 2099, 10.1002/jnr.21349 · DOI · Paper page
  54. Kramer, 2015, The impact of chronic liraglutide therapy on glucagon secretion in type 2 diabetes: insight from the libra trial, J Clin Endocrinol Metab, 100, 3702, 10.1210/jc.2015-2725 · DOI · Paper page

Cited by

See all 105

Metadata

Authors
Farr, O. M., Tsoukas, M. A., Triantafyllou, G., Dincer, F., Filippaios, A., Ko, B.-J., & Mantzoros, C. S.
Venue
Metabolism
Publisher
Elsevier BV
Published
2016-07
Volume
65
Issue
7
Pages
945-953
ISSN
0026-0495 (ISSN-L)
OpenAlex
W2298314932
Cited by
105
References
24
FWCI
5.63
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • National Center for Research Resources
  • Harvard Catalyst (UL1 RR025758)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (5T32HD052961)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study. https://app.cochat.ai/papers/10.1016/j.metabol.2016.03.009
The paper
Farr, O. M., Tsoukas, M. A., Triantafyllou, G., Dincer, F., Filippaios, A., Ko, B.-J., & Mantzoros, C. S. (2016). Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study. Metabolism. https://doi.org/10.1016/j.metabol.2016.03.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.